Advertisement

La sclerosi multipla

Chapter
  • 201 Downloads
Part of the Aspetti psico-sociali della sclerosi multipla book series (APSSM, volume 4)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):939–952CrossRefGoogle Scholar
  2. 2.
    Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191PubMedCrossRefGoogle Scholar
  3. 3.
    Amato MP, Ponziani G (1999) Quantification of impairment in MS: discussion of the scales in use. Mult Scler 5(4):216–219PubMedCrossRefGoogle Scholar
  4. 4.
    Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452PubMedGoogle Scholar
  5. 5.
    Grimaud J, Auray JP, Collectif sep des villes et sep des champs (2004) Quality of life and economic cost of multiple sclerosis. Rev Neurol 160(1):23–34PubMedGoogle Scholar
  6. 6.
    The IFNB multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43(4):655–661Google Scholar
  7. 7.
    Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscolar interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 39(3):285–294PubMedCrossRefGoogle Scholar
  8. 8.
    PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498–1504Google Scholar
  9. 9.
    Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, doubleblind, placebo-controlled trial. Neurology 45(7):1268–1276PubMedGoogle Scholar
  10. 10.
    European study group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491–1497Google Scholar
  11. 11.
    Hartung HP, Gonsette R, Konig N et al (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018–2025PubMedCrossRefGoogle Scholar
  12. 12.
    Goodin DS, Frohman EM, Garmany GP jr et al (2002) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2):169–178PubMedGoogle Scholar
  13. 13.
    Panitch H, Goodin DS, Francis G et al (2002) Evidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59(10):1496–1506PubMedGoogle Scholar
  14. 14.
    Durelli L, Verdun E, Barbero P et al (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta 1-a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316):1453–1460PubMedCrossRefGoogle Scholar
  15. 15.
    Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904PubMedCrossRefGoogle Scholar
  16. 16.
    Comi G, Filippi M, Barkhof F et al (2001) Early treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582PubMedCrossRefGoogle Scholar
  17. 17.
    Filippini G, Munari L, Incorvaia B et al (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361(9357):545–552PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2005

Authors and Affiliations

There are no affiliations available

Personalised recommendations